Latest Ratios: P/E Ratio -3.8x · EV/EBITDA N/A · ROE -45.2%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $12M | $16M | $39M | $52M | — | — | — | — |
| Enterprise Value | $10M | $14M | $36M | $46M | — | — | — | — |
| P/E Ratio → | -3.85 | — | — | — | — | — | — | — |
| P/S Ratio | 47.66 | 62.63 | 754.46 | 179.27 | — | — | — | — |
| P/B Ratio | 1.70 | 2.27 | 5.92 | 6.11 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 56.13 | 691.00 | 156.98 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -277.7% | -277.7% | 100.7% | 131.4% | — | 96.9% | 92.2% | — |
| Operating Margin | -1416.0% | -1416.0% | -5049.8% | -1101.0% | — | -1661.4% | -2233.0% | — |
| Net Profit Margin | -1227.1% | -1227.1% | -3621.1% | -1077.8% | — | -1822.3% | -3266.1% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -45.2% | -45.2% | -24.9% | -69.9% | -192.5% | -134.5% | -164.3% | -44.4% |
| ROA | -39.7% | -39.7% | -22.5% | -47.2% | -54.0% | -41.5% | -58.0% | -29.2% |
| ROIC | -61.6% | -61.6% | -73.4% | -107.8% | -52.1% | -47.4% | -41.9% | — |
| ROCE | -49.5% | -49.5% | -33.3% | -66.5% | -108.6% | -88.6% | -73.9% | -25.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.05 | 0.04 | 7.20 | 1.26 | 6.27 | 0.35 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.24 | -0.50 | -0.76 | 4.50 | 0.29 | 4.40 | 0.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -219.71 | -219.71 | -123.83 | -78.98 | -15.30 | -14.74 | -12.52 | — |
Net cash position: cash ($2M) exceeds total debt ($482562)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.17 | 5.17 | 9.89 | 14.08 | 0.60 | 1.12 | 0.54 | 1.46 |
| Quick Ratio | 5.17 | 5.17 | 8.51 | 13.14 | 0.46 | 0.97 | 0.45 | 1.33 |
| Cash Ratio | 2.95 | 2.95 | 8.19 | 12.55 | 0.38 | 0.86 | 0.34 | 1.22 |
| Asset Turnover | — | 0.03 | 0.01 | 0.03 | — | 0.02 | 0.02 | — |
| Inventory Turnover | — | — | 0.04 | 0.01 | 0.19 | 0.01 | 0.02 | — |
| Days Sales Outstanding | — | 194.14 | 96.52 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $12M | $12M | $11M | $8M | $7M | $6M | $6M |
Insufficient liquidity for operations
Based on reported figures, GDTC trades at a P/S ratio of 48.61, a valuation that appears to reflect speculative interest in its iPSC platform rather than current commercial output, especially when compared to the broader biotech sector's historical norms for pre-clinical, non-revenue-generating entities.
The elevated P/S multiple suggests that investors are pricing the company based on the potential of its gamma delta T cell pipeline rather than its current financial performance. This valuation warrants caution, as the lack of a clear path to commercialization makes traditional multiples like P/E or EV/EBITDA largely irrelevant for assessing the company's intrinsic value.
As reported in recent financial statements, GDTC's ROIC of -30.3% in 2025Q4 highlights a persistent inability to generate returns on invested capital, a trend that has remained consistently negative over the past ten quarters as the company prioritizes R&D over operational efficiency.
The negative ROIC is a structural byproduct of the company's high-burn, pre-clinical business model where capital is consumed to build laboratory infrastructure rather than to generate earnings. Investors should monitor whether future clinical milestones can eventually drive a shift toward positive returns, though current trends suggest continued capital erosion.
According to quarterly filings, GDTC's asset turnover remains stagnant at 0.02, indicating that the company's significant investment in laboratory infrastructure has yet to translate into meaningful revenue generation or improved operational throughput relative to its asset base.
The extremely low asset turnover ratio suggests that the company's capital-intensive manufacturing setup is currently underutilized. This inefficiency is typical for early-stage biotech firms, but it underscores the risk that the company may struggle to scale its operations without further significant capital injections.
Based on the latest quarterly data, GDTC's current ratio has declined to 5.17 from a peak of 36.42 in 2023Q2, signaling that the company's liquidity buffer is rapidly depleting as it funds ongoing clinical development without a self-sustaining revenue stream.
While a current ratio of 5.17 might appear healthy in isolation, it masks the reality of a high cash burn rate that threatens to exhaust available resources within a short timeframe. The company's reliance on cash reserves to cover operating losses suggests that liquidity will remain a primary concern until a major partnership or financing event occurs.
Analysts frequently misapply P/S ratios to GDTC, which obscures the fact that the company's revenue is incidental grant funding rather than commercial sales, making this metric a poor proxy for assessing the underlying health or growth trajectory of the business.
Using revenue-based valuation for a pre-clinical biotech firm like GDTC is fundamentally flawed because it ignores the binary nature of clinical trial outcomes. Instead of P/S, investors should focus on cash runway and the progress of clinical milestones, as these are the true drivers of value for a company in this stage of development.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GDTC stock.
CytoMed Therapeutics Limited's current P/E ratio is -3.8x. This places it at the 50th percentile of its historical range.
CytoMed Therapeutics Limited's return on equity (ROE) is -45.2%. The historical average is -96.5%.
Based on historical data, CytoMed Therapeutics Limited is trading at a P/E of -3.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
CytoMed Therapeutics Limited has -277.7% gross margin and -1416.0% operating margin.